FILING ANALYSIS · THURSDAY, NOVEMBER 5
Xeris Biopharma Holdings, Inc. XERS — 8-K: Results of Operations and Financial Condition
positive
Xeris Biopharma reported a 44% year-over-year increase in total revenue to $107 million, driven by strong growth in Recorlev sales, and raised its full-year 2026 revenue guidance to $395-405 million. The company also increased its 2030 total revenue outlook to over $1 billion, up from approximately $750 million.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →